SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.
According to SD BioSensor, Inc's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.95. At the end of 2022 the company had a P/S ratio of 0.99.
Year | P/S ratio |
---|---|
2023 | 1.95 |
2022 | 0.99 |
2021 | 1.86 |
2020 | 3.72 |
2019 | 85.91 |
2018 | 95.51 |